Table: q1_q4_2020_prescription_drugs_intro_to_market , manufacturer_name like E*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name ndc_number drug_product_description date_introduced_to_market wac_at_introduction marketing_pricing_plan_description marketing_pricing_plan_non_public_indicator estimated_number_of_patients breakthrough_therapy_indicator priority_review_indicator acquisition_date acquisition_price acquisition_price_non_public_indicator acquisition_price_comment general_comments supporting_documents
Edenbridge Pharmaceuticals, LLC 42799070815 Miglustat Capsules, 100mg 2020-09-01 4018.5300 None 1 100 None None None None None None None None
Eli Lilly and Company 00002298026 Retevmo™ 80MG 120 CAPSULE 2020-05-12 20600.0000 None 1 3750 1 1 2019-02-15 None 1 Lilly acquired Loxo Oncology, Inc, on February 15, 2019 for a purchase price of approximately $6.92 billion, net of cash acquired. Under the terms of the agreement, Lilly acquired a pipeline of investigational medicines, including selpercatinib (Loxo-292). [https://investor.lilly.com/static-files/cd4a37af-ec28-449c-9bfb-ae380700209a] Retevmo™ (selpercatinib) was approved by the FDA in May 2020 as the first therapy specifically indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), and the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Surveillance, Epidemiology, and End Results (SEER) data were used to estimate rates of cancer incidence and metastatic disease. Publicly available peer-reviewed literature was reviewed to estimate the prevalence of RET alterations and rates of disease progression by tumor type. Based on this analysis, Lilly estimates that there are 2,500 – 5,000 patients who may be eligible for treatment with a RET kinase inhibitor such as Retevmo. The average of that range (3,750) is reflected in column H. Patients with these conditions may or may not take Retevmo. All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. None
Eli Lilly and Company 00002298060 Retevmo™ 80MG 60 CAPSULE 2020-05-12 10300.0000 None 1 3750 1 1 2019-02-15 None 1 Lilly acquired Loxo Oncology, Inc, on February 15, 2019 for a purchase price of approximately $6.92 billion, net of cash acquired. Under the terms of the agreement, Lilly acquired a pipeline of investigational medicines, including selpercatinib (Loxo-292). [https://investor.lilly.com/static-files/cd4a37af-ec28-449c-9bfb-ae380700209a] Retevmo™ (selpercatinib) was approved by the FDA in May 2020 as the first therapy specifically indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), and the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Surveillance, Epidemiology, and End Results (SEER) data were used to estimate rates of cancer incidence and metastatic disease. Publicly available peer-reviewed literature was reviewed to estimate the prevalence of RET alterations and rates of disease progression by tumor type. Based on this analysis, Lilly estimates that there are 2,500 – 5,000 patients who may be eligible for treatment with a RET kinase inhibitor such as Retevmo. The average of that range (3,750) is reflected in column H. Patients with these conditions may or may not take Retevmo. All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. None
Eli Lilly and Company 00002397760 Retevmo™ 40MG 60 CAPSULE 2020-05-14 6866.6600 None 1 3750 1 1 2019-02-15 6920000000.0000 None Lilly acquired Loxo Oncology, Inc, on February 15, 2019 for a purchase price of approximately $6.92 billion, net of cash acquired. Under the terms of the agreement, Lilly acquired a pipeline of investigational medicines, including selpercatinib (Loxo-292). Based on guidance from OSHPD, Lilly has entered the acquisition cost of Loxo Oncology, Inc. in the Acquisition Price field. [https://investor.lilly.com/static-files/cd4a37af-ec28-449c-9bfb-ae380700209a] Retevmo™ (selpercatinib) was approved by the FDA in May 2020 as the first therapy specifically indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), and the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, or advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Surveillance, Epidemiology, and End Results (SEER) data were used to estimate rates of cancer incidence and metastatic disease. Publicly available peer-reviewed literature was reviewed to estimate the prevalence of RET alterations and rates of disease progression by tumor type. Based on this analysis, Lilly estimates that there are 2,500 – 5,000 patients who may be eligible for treatment with a RET kinase inhibitor such as Retevmo. The average of that range (3,750) is reflected in column H. Patients with these conditions may or may not take Retevmo. All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=438
Epizyme, Inc. 72607010000 Tazverik (Tazemetostat) 200 mg Tablets 2020-01-31 15500.0000 None 1 138 None 1 None None None None None None
Eton Pharmaceuticals, Inc. 71863011050 Alkindi Sprinkle 1mg 2020-09-29 698.6400 None 1 8000 None None None None None None Eton does not have patented marketing information. Any marketing information related to this product is know only to Eton’s Commercial team. Marketing information has potential commercial value and allowing this information to remain non-public and confidential, allows Eton to obtain a business advantage over its competitors who do not have or know Eton’s marketing information. Making the marketing information public would not serve the public interest and therefore disclosure is not required. The prevalence of patients in the US that have the condition for which our prescription drug is prescribed, children between the ages of 0 -17, is estimated to be between 5,000 and 11,000. For reporting purposes, we entered the midpoint of 8,000. None
Eton Pharmaceuticals, Inc. 71863011150 Alkindi Sprinkle 2mg 2020-09-29 1397.2800 None 1 8000 None None None None None None Eton does not have patented marketing information. Any marketing information related to this product is know only to Eton’s Commercial team. Marketing information has potential commercial value and allowing this information to remain non-public and confidential, allows Eton to obtain a business advantage over its competitors who do not have or know Eton’s marketing information. Making the marketing information public would not serve the public interest and therefore disclosure is not required. The prevalence of patients in the US that have the condition for which our prescription drug is prescribed, children between the ages of 0 -17, is estimated to be between 5,000 and 11,000. For reporting purposes, we entered the midpoint of 8,000. None
Eton Pharmaceuticals, Inc. 71863011250 Alkindi Sprinkle 5mg 2020-09-29 3493.2000 None 1 8000 None None None None None None Eton does not have patented marketing information. Any marketing information related to this product is know only to Eton’s Commercial team. Marketing information has potential commercial value and allowing this information to remain non-public and confidential, allows Eton to obtain a business advantage over its competitors who do not have or know Eton’s marketing information. Making the marketing information public would not serve the public interest and therefore disclosure is not required. The prevalence of patients in the US that have the condition for which our prescription drug is prescribed, children between the ages of 0 -17, is estimated to be between 5,000 and 11,000. For reporting purposes, we entered the midpoint of 8,000. None
Exelan Pharmaceuticals, Inc. 76282067630 Cinacalcet HCl Oral Tablet 90 MG, 30ct 2020-06-15 956.4900 None 1 454848 None None None None None None Full Drug Description: Cinacalcet HCl Oral Tablet 90 MG, 30ct None